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HIVBackground: Accurate and timely diagnosis of tuberculosis (TB) is key to effective treatment and manage-
ment. This study was designed to compare the diagnostic performance of GeneXpert and Ziehl-Neelson
(ZN) microscopy test using culture as the reference.
Methods: Cross-sectional study was conducted in a tertiary hospital to compare the performance of
GeneXpert and ZN test among HIV and non-HIV patients. Sputum samples were collected from 261 sus-
pected TB patients and analyzed in the laboratory using GeneXpert, ZN test and culture. Statistical anal-
ysis included calculation of sensitivity, specificity, positive predictive value and negative predictive value.
v2 was used to compare the outcome of diagnostic test and demographic variables. p-value < 0.05 was
considered significant.
Results: Comparison of TB prevalence among urban versus rural areas using the three diagnostic tests
are: ZN test: 32 (12.3%) vs 16 (6.1%; v2 7.63, P = 0.007); GeneXpert: 63 (16.1%) vs 20 (7.7%, v2 9.01,
P = 0.003) and culture: 22 (8.4%) vs 10 (3.8% v2 4.44, P = 0.05). Also, prevalence of TB was significantly
(P < 0.05) higher among HIV negative 25 (9.6%) than HIV positive 23 (8.8%) patients. The overall preva-
lence of rifampicin resistance was 12 (4.60%). Out of 261 sputum samples examined for TB, 48
(18.38%) tested positive by ZN test, 62 (23.76%) by GeneXpert and 32 (12.26%) by culture. Two out of
32 samples that tested positive by culture were negative by GeneXpert. GeneXpert had higher sensitivity
(93.75%) than ZN test (50.00%). However, they had equal specificity (86.03%). The sensitivity and speci-
ficity of ZN and GeneXpert among HIV patients was 58.33% (95% CI = 29.66–84.83) and 79.31% (95%
CI; 69.24–87.26) and 91.67% (95% CI 61.51–99.79) and 80.67 (95% CI; 70.58–88.17) while among HIV neg-
ative patients; ZN test and GeneXpert assay had 45.00% (23.05–68.45) and 90.14% (84.04–94.50) and
95.00% (75.13–99.87) and 89.44% (83.13–93.96), respectively.
Conclusion: GeneXpert demonstrated higher level of performance than ZN microscopy. We recommend
the use of GeneXpert for diagnosis of TB in Benue State and Nigeria in general for effective treatment
and management of tuberculosis.
 2018 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tuberculosis (TB) is an infectious disease caused by members
of the genus Mycobacterium. Nine species in the genus are referred
to as Mycobacterium tuberculosis complex (MTBC).1–3 Among
the MTBC, Mycobacterium tuberculosis (MTB), M. africanum and
M. canetti are the frequent etiologic agents of TB in humans.
530 E.F. Ejeh et al. / Alexandria Journal of Medicine 54 (2018) 529–533However, M. bovis which has the widest host range and the
common cause of TB in animals also cause TB in man, known as
zoonotic tuberculosis.4,5 Tuberculosis is a major global public
health challenge and accounts for over 9.0 million new cases and
about 1.5 million deaths annually.6
Nigeria, the largest black nation in the world has a human pop-
ulation of over 196 million. Nigeria is ranked second in Africa and
among 22 high burdened TB countries worldwide.7 Benue State in
Nigeria has high TB prevalence due to poverty and HIV/AIDS.8–10
Tuberculosis diagnosis and treatment is free in Benue State at all
level.11 However, the diagnosis of TB is fraught with challenges
not only in Benue State but in most TB endemic settings world-
wide. The conventional methods of TB diagnoses such as acid-
fast microscopy (AFB), culture, phenotypic drug susceptibility test
(DST) are unable to correctly detect MTBC, time consuming and
require special laboratory and expertise.12 Other diagnostic tech-
niques like X-ray and clinical diagnosis based on symptoms are
subjective and expose patients to radiation hazards. Therefore, effi-
cient treatment and management of TB require rapid, accurate and
safe methods of diagnosis.13
In recent time, molecular diagnostic technique have been devel-
oped to address these issues. These include line probe assay (LPAs),
PCR based RD-typing, spoligotyping, real time PCR and GeneXpert
MTB/RIF (GeneXpert).14–18
The GeneXpert is an automated technology that rapidly and
simultaneously process sputum specimen and detect MTBC as well
as rifampicin resistance mutation in the rpoB gene.19 This assay
was approved and recommended for diagnosis of TB byWHO espe-
cially suspected HIV-TB comorbidity globally.20 However, clinical
diagnosis and detection of AFB are the common routine diagnostic
test for TB in Benue State, Nigeria. Therefore, the aim of this study
was to compare the diagnostic performance of GeneXpert and AFB
test using solid culture as reference.2. Materials and methods
2.1. Study design and criteria
A cross-sectional study was conducted to evaluate the diagnos-
tic performance of AFB test and GeneXpert assay in a tertiary hos-
pital in Benue State, Nigeria. Study participants were recruited
based on the following criteria.
2.2. Inclusion criteria
 Availability of test results for AFB test, GeneXpert and culture.
 All ages
 Ability to produce sputum without inducement
 Suspected TB patient based on clinical symptoms
2.3. Exclusion criteria
 Unknown HIV status
 Extrapulmonary TB
 Induced sputum sample collection
 Non-respiratory specimen
 Sputum sample less than 3 ml
 Invalid and error results from GeneXpert
2.4. Study participants and sample collection
Individuals of all ages who were clinically diagnosed as sus-
pected TB patients were included in the study. All patients who
consented after counseling about HIV were tested for HIV infec-
tion. Patient’s information was collated from hospital recordsfollowing approval from appropriate authority. Portion of sputum
sampled from routine AFB test and GeneXpert were collected and
stored at 20 C for an average of 4 weeks. Thereafter, it was
transported from Federal Medical Centre, Makurdi to Tuberculosis
Laboratory, Department of Veterinary Public Health and Preventive
Medicine, University of Ibadan for microbiological culture.2.5. Microbiological analyses
2.5.1. Acid-fast microscopy
Using a sterile application stick, a drop of raw sputum was
placed on a grease free glass slide and evenly spread, dried, and
heat fixed. Thereafter, Ziehl-Neelson staining was done according
to previously described methods.212.5.2. GeneXpert
GeneXpert test was performed according to manufacturer’s
instruction. Briefly, with the aid of a sterile pipette, 2 ml of GeneX-
pert reagent was added to 1 ml of sputum sample and incubated at
room temperature for 15 min. The mixture was agitated twice at
5 min interval. The liquefied mixture was transferred into the Gen-
eXpert cartridge using a sterile pipette and loaded into GeneXpert
instrument. Results was available within 2 h.2.5.3. Culture and identification
The remaining sputum sample was processed using N-acetyl-L-
cysteine-NaOH (NALC-NaOH) method as earlier described.14
Briefly, equal volume of freshly prepared NALC-NaOH was added
to the remaining sputum sample (variable volume of sputum) vor-
texed and then incubated for 15 min at room temperature. The
mixture was neutralized by adding phosphate buffer (pH 6.8)
two times it’s volume. It was then centrifuged at 3000g for
20 min. The supernatant was discarded, and the residue was re-
suspended in 2 ml phosphate buffer, 0.5 ml of the concentrated
cells was inoculated on to Lowenstein-Jensen (LJ) media and incu-
bated for 8–12 weeks at 37 C. Colony suspected of MTBC was
tested using AFB microscopy and confirmed with the aid of SD Bio-
line assay.2.5.4. SD Bioline assay
The isolates were subjected to SD Bioline TB AgMPT64 analy-
sis. The test was done according to the manufacturer’s instructions.
This test consisted of test cassette which consists of a sample pad, a
gold conjugate, a nitrocellulose membrane, and an absorbent pad.
Mouse monoclonal anti-MPT64 was immobilized on the nitrocellu-
lar membrane as the capture material (test line). Another antibody,
which recognized another epitope of MPT64, conjugated with col-
loidal gold particles were used for antigen capture and detection in
a sandwich type assay. The cassette has a letter T and C as test line
and control line, respectively on the surface of the case. Positive
results produced red to purple band. Absence of band on the con-
trol line was regarded as invalid.2.6. Statistical analyses
Data obtained were cross tabulated, v2 was used to compare
differences in TB detection rate among demographic variable using
SPSS version 17. Results obtained were considered significant at a
level of P value < 0.05. Sensitivity, specificity, positive predictive
value and negative predictive value was performed at 95%
confidence interval using GraphPad InStat version 3.05 for
Windows (GraphPad Software, San Diego California USA,
www.graphpad.com).
Table 2







AFB Test Positive 16 32 48
Negative 16 197 213
Total 32 229 261
GeneXpert Positive 30 32 62
Negative 2 197 199
Total 32 229 261
Table 3
Comparison of the performance of AFB test and GeneXpert assay among TB patients in
Benue state.
Parameters AFB test 95% C.I. GeneXpert 95% C.I.
SEN 50.00 31.87–68.13 93.75 79.18–99.23
SPE 86.03 80.89–90.25 86.03 80.89–90.25
PPV 33.33 20.38–48.46 48.39 35.49–61.44
NPV 92.49 88.09–95.65 98.99 96.42–99.88
SEN = Sensitivity, SPE = Specificity, PPV = Positive predictive value, PPN = Negative
predictive value.
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3.1. Demographics and tuberculosis detection rate
Prevalence of TB was not statistically different among sex and
age group for all three diagnostic tests (Table 1). We observed sig-
nificant difference in the prevalence of TB between rural and urban
areas. Patients from urban area had higher TB detection rate by AFB
32 (12.3%), v2 = 7.63, P = 0.007), GeneXpert 42 (16.1%), v2 = 9.01,
P = 0.003) and culture 22 (8.4%) v2 = 4.44, P = 0.05) compared with
patients from rural area. Comparing the results of GeneXpert by
ethnicity we found out that there was significant difference
(P = 0.007) in the prevalence of TB among different ethnic groups
in Benue State. The Idoma ethnic group had the highest TB preva-
lence 32 (12.3%) (S1). Results from AFB showed that prevalence of
TB was significantly (P = 0.032) higher among HIV negative 25
(9.6%) than HIV positive 23 (8.8%) patients. Rifampicin resistance
was detected among 12 (4.60%) patients by GeneXpert assay.
Patients from rural areas had higher rifampicin resistance (7
(2.7%) than those from urban areas (P = 0.002) (Table 1).
3.2. AFB and GeneXpert diagnostic performance
A total of 261 sputum specimens from suspected TB patients
were tested for tuberculosis by AFB test, GeneXpert and microbio-
logical culture. 48 (18.39%) were detected by AFB test, 62 (23.76%)
by GeneXpert, 40 (24.70) of the samples were positive by culture
and identified by AFB as mycobacteria. 8 (20.00%) samples were
positive by culture and either positive or negative by AFB and 4
(10.00%) were positive by culture and AFB but negative by SD-
Bioline assay. 32 (12.26%) was confirmed by SD-Boiline assay as
MTBC. Among the 32 samples that were positive by culture, 2
(6.25%) were GeneXpert negative. 229 (87.74%) specimens were
negative for mycobacteria. The rate of contamination was observed
to be very high. 16 (33.33%) of the 48 samples that were positive by
AFB also grew MTBC (Table 2).
The overall sensitivity, specificity, positive predictive value and
negative predictive value for AFB Test and GeneXpert when culture
was used as a reference standard (Table 3). GeneXpert had higher
sensitivity (93.75%) than AFB test (50.00%). However, both test had
equal specificity (86.03%). The positive predictive value was poor
for AFB test and GeneXpert assay (Table 3).Table 1
Demographic data and detection rates of AFB Microscopy, GeneXpert and Culture suspect
Variables No Sampled (%) AFB Test (%) v2 P value GeneXpert (%)
Sex
Male 132 (50.6) 23 (8.8) 0.166 0.402 37 (14.7)
Female 129 (49.4) 25 (9.6) 25 (9.6)
Age group
0 – 14 15 (5.7) 1 (0.4) 3.076 0.380 3 (1.1)
15 – 34 104 (39.8) 20 (7.7) 24 (9.2)
35 – 54 96 (36.8) 21 (8.9) 25 (9.6)
 55 46 (17.6) 6 (2.3) 10 (3.8)
Location
Urban 211 (80.8) 32 (12.3) 7.632 0.007 42 (16.1)
Rural 50 (19.2) 16 (6.1) 20 (7.7)
Ethnicity
Tiv 144 (55.2) 21 (8.0) 0.201 24 (9.2)
Idoma 93 (35.6) 22 (8.4) 32 (12.3)
others 24 (9.2) 5 (1.9) 6 (2.3)
HIV Status
HIV Positive 99 (37.9) 25 (9.6) 5.004 0.032 28 (10.3)
HIV Negative 162 (62.1) 23 (8.8) 34 (13.0)Furthermore, AFB test was able to detect TB among HIV positive
patients than HIV Negative patients. However, we observed that
GeneXpert had 91.67% and 95.00% sensitivities among HIV positive
and HIV negative patients respectively (Tables 4 and 5).4. Discussion
The findings of this study revealed high TB prevalence among
urban dwellers than patients from rural area using the three diag-
nostic tests. This finding agreed with study conducted in Enugu
State, Nigeria where Oshi et al.12 reported a frequency of 68.1%
TB among urban dwellers compared to 31.9% among patients from
rural area. Similarly, TB in the European Union had been reported
to be concentrated in big cities. It was also noted that immigrants,
homeless people, drug misuse and alcohol intake are risk factors
for high TB prevalence in urban area.22 Globally, WHO alsoed TB Patients
v2 P value RIF (%) v2 P value Culture (%) v2 P value
2.695 0.067 8 (3.1) 1.303 0.200 20 (7.7) 2.075 0.105
4 (1.5) 12 (4.6)
0.524 0.914 0 (0.0) 1.911 0.591 2 (0.8) 0.485 0.922
6 (2.3) 14 (5.4)
3 (1.1) 10 (3.8)
3 (1.1) 6 (2.3)
9.012 0.003 5 (1.9) 12.465 0.002 22 (8.4) 4.444 0.058
7 (2.7) 10 (3.8)
9.843 0.007 6 (2.3) 0.200 0.905 13 (5.0) 5.275 0.072
5 (1.9) 13 (5.0)
1 (0.4) 6 (2.3)
1.806 0.117 5 (1.9) 0.075 0.503 12 (4.6) 0.003 0.561
7 (2.7) 20 (7.7)
Table 5
Comparison of the performance of AFB test and GeneXpert assay among non-HIV
patients in Benue state.
Parameters AFB test 95% C.I. GeneXpert 95% C.I.
SEN 45.00 23.05–68.45 95.00 75.13–99.87
SPE 90.14 84.04–94.50 89.44 83.18–93.96
PPV 39.13 19.73–61.44 55.88 37.86–72.84
NPV 92.09 86.26–95.98 99.22 95.72–99.98
SEN = Sensitivity, SPE = Specificity, PPV = Positive predictive value, PPN = Negative
predictive value.
Table 4
Comparison of the performance of AFB test and GeneXpert assay among HIV patients
in Benue state.
Parameters AFB test 95% C.I. GeneXpert 95% C.I.
SEN 58. 33 29.66–84.83 91.67 61.51–99.79
SPE 79.31 69.24–87.26 80.67 70.58–88.17
PPV 28.00 12.07–49.43 39.29 21.51–59.42
NPV 93.24 84.91–97.77 98.59 92.40–99.96
SEN = Sensitivity, SPE = Specificity, PPV = Positive predictive value, PPN = Negative
predictive value.
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area.7 However, in countries where most of the people live in rural
area, it was noted that the prevalence of TB was higher among rural
dwellers than urban residents and this was attributed to lack of
adequate diagnosis and treatment facilities in rural areas.7 Con-
versely, we noticed a significantly higher rifampicin resistant
among TB patients from rural area than patients from urban area.
This observation may be due to failure to adhere to treatment
regime, non-availability and accessibility of diagnostic facilities
to correctly and timely diagnose rifampicin resistance among rural
dwellers.
Ethnicity is not regarded as an important risk factor for TB.
Though, other factors that relate with ethnicity such as believe,
social education, social behavior, family size, economic activities,
social status, housing and food (nutrition) may influence the con-
tribution of ethnicity to prevalence of TB in the community. In this
study we observed that the Idoma ethnic group had high TB preva-
lence with respect to AFB test only. There was no significant differ-
ence between Idoma ethnic group and the prevalence of TB when
GeneXpert and culture were considered. In a similar study in Tai-
wan, the Han Chines were found to have less TB incidence than
the aborigines in Taiwan tribes.23 Also, low prevalence of TB was
reported among the Afar ethnic group in Ethiopia.24 The high
prevalence of TB among the Idoma ethnic group in this study could
have resulted from the inability of AFB to differentiate between
MTBC and NTM.25
Our finding indicated a substantially high TB among HIV
patients than non-HIV patients considering AFB test alone. Though,
there was no significant difference between the occurrence of TB
among HIV and non-HIV when GeneXpert and culture were used.
This may be because AFB unlike GeneXpert and culture is unable
to differentiate between MTBC and NTM. More so, it is a known
fact that HIV patients are susceptible to NTM infections due to
their immunodeficiency status. Furthermore, smear microscopy
(Acid-fast bacilli, AFB) test is the most common diagnostic tool
for detection of TB in developing countries. However, AFB test
has poor sensitivity and limited specificity; since AFB test often
tend to miss TB detection among patients with very low mycobac-
terial load in their sputum. Hence, this test cannot differentiate
between MTBC and NTM. Despite the introduction and recommen-
dation of molecular based diagnostic devices such as line probe
assay and GeneXpert for diagnosis of TB, AFB test is still used inpoor resource countries like Nigeria due to inadequate infrastruc-
ture and access to basic amenities like regular power supply which
are necessary for sustainable use of these devices.
Our findings revealed that GeneXpert was able to detect 14
cases that were missed by AFB and two cases that were culture
positive but negative by GeneXpert. This finding was consistent
with previous studies that evaluated the performance of GeneX-
pert and AFB test.26,27 The reason for the false positive result by
GeneXpert may be due to presence of PCR inhibitors and low bac-
terial load.29 The overall sensitivity and specificity of AFB test in
this study were 50.0% and 80.89% which were lower than results
obtained in a previous study in Thailand, where sensitivity and
specificity of AFB test was reported to be 60.5% and 98.5%.28 How-
ever, Zaka et al.29 reported a lower sensitivity (43.5%) and higher
specificity (99.5%) of AFB test among pulmonary TB patients in
Turkey. Also, the sensitivity and of GeneXpert was found to be
93.75% and the specificity was the same as that of AFB test in this
study. Data from previous report showed that GeneXpert had
higher sensitivity and specificity than AFB test.25,28,29 However,
Bajrami et al.30 reported higher sensitivity and specificity of AFB
than GeneXpert in a comparative study in Kosovo. The reason for
the variation of the sensitivity and specificity of GeneXpert and
AFB test in various studies could be due to differences in study
design, sample processing, storage and transportation. The perfor-
mance of GeneXpert assay in detecting TB among HIV patients was
higher compared with AFB test. This finding was consistent with
previous results.31 Nevertheless, in a similar study among HIV
infected prisoners in Malaysia, Al-Darraji et al.32 reported a low
GeneXpert sensitivity (53.3%, 95% CI 30.12–75.2%) and further
observed that GeneXpert-negative active TB patients had less
advanced HIV infection. Al-Darraji et al.32 explained that the low
sensitivity reported in the study may be due to low bacillary load
given that GeneXpert requires a minimum of 131 bacilli/ml com-
pare to 10–100 bacilli/ml for culture. Also, Cavanaugh et al.27
reported that in patients living with HIV, GeneXpert significantly
increased diagnostic yield compared to AFB test and that the high-
est yield was obtained when GeneXpert was used to test speci-
mens from patients with CD4 count <100 cells/ll. In another
study conducted among HIV patient to evaluate the effect of spu-
tum concentration without NALC-NaOH, concentration of sputum
treated with NALC-NaOH and filtration through small-membrane
filter on the performance of smear microscopy (AFB test). It was
observed that small-membrane filter method significantly
increases the sensitivity and specificity of AFB test.33 However,
in this study AFB test was performed on direct smear without con-
centration, treatment with NALC-NaOH or filtration through small-
membrane filter and may be the reason for the poor performance
of AFB test among HIV patients and the general performance of
AFB test in this study.5. Conclusions
In conclusion, we found that the performance of GeneXpert was
superior to AFB test. However, GeneXpert assay had significantly
higher sensitivity but lower specificity among non-HIV patients
compared to AFB test. Importantly, we also found the prevalence
of TB to be higher among urban patients. Conversely, we confirmed
a significantly higher rifampicin resistant tuberculosis among
patients from rural areas.
Overall, we recommend the use of GeneXpert for rapid and
accurate diagnosis of TB in Benue State and other TB endemic set-
tings of the world. This will ultimately help to detect cases that
may have been missed by AFB test and since GeneXpert could
detect RR-TB, improve diagnosis and enhance patient treatment
and management.
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